Novo Nordisk hits out as Dutch agency advises against insurance cover for Wegovy
Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance
![The institute said even though Wegovy is effective for losing weight, more research is needed to determine the actual health effects](https://static.independent.co.uk/2024/05/13/23/13140710-1fd3b1bd-0d23-4a13-845e-07dfebc867fc.jpg)
Support truly
independent journalism
Our mission is to deliver unbiased, fact-based reporting that holds power to account and exposes the truth.
Whether $5 or $50, every contribution counts.
Support us to deliver journalism without an agenda.
![Louise Thomas](https://static.independent.co.uk/static-assets/support-us/louise-thomas.png)
Louise Thomas
Editor
Danish drugmaker Novo Nordisk said it was disappointed with the recommendation to the Netherlands government to not cover its hugely popular weight-loss drug Wegovy under the country’s basic insurance.
The Dutch Health Care Institute said on Tuesday in its advice to the healthcare minister said it was unclear whether the health effects of Wegovy were large enough to weigh up against the costs of the medicine.
The institute said even though Wegovy is effective for losing weight, more research is needed to determine the actual health effects.
“While we are pleased that the Dutch Health Care Institute recognises the necessary role of medications in the fight against obesity as a chronic disease, we are obviously disappointed in their initial decision,” a Novo Nordisk spokesperson said in an email.
With around 4 million people in the Netherlands likely to benefit from Wegovy, the institute said total costs for the government could rise to around 1.3 billion euros ($1.42 billion). Wegovy is not yet for sale in the country, Novo said.
Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance for a limited group of patients.
The institute also flagged concern about the global shortage of the medicine’s main ingredient, semaglutide, which is vital for the treatment of diabetes.
“These shortages emphasize the importance of critically weighing which people have the largest benefit from a medicine,” it said.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments